Patents by Inventor Maj Hedtjarn

Maj Hedtjarn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Manufacture of Antisense Oligomers and Conjugates Targeting PCSK9
    Publication number: 20180312846
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
    Publication number: 20180216116
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 2, 2018
    Inventors: Nanna Albaek, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Oligonucleotide conjugates
    Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Compositions and methods for modulation of FGFR3 expression
    Patent number: 9725723
    Abstract: Disclosed are oligonucleotides which target and hybridize to nucleic acid molecules encoding FGFR3, leading to reduced expression of FGFR3. Reduction in the aberrant expression of FGFR3 is beneficial for the treatment of certain medical disorders, such as achondroplasia.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: August 8, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Maj Hedtjarn, Soren Ottosen
  • OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
    Publication number: 20170191064
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • OLIGONUCLEOTIDE CONJUGATES
    Publication number: 20160138025
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF
    Publication number: 20160130582
    Abstract: The present invention provides, among other things, oligonucleotide modulators (e.g., inhibitors) of B cell lymphoma/leukemia 11A (BCL11A) and improved methods and composition for treating BCL11A-related diseases, disorders or conditions based on such modulators.
    Type: Application
    Filed: May 26, 2014
    Publication date: May 12, 2016
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Maj HEDTJÄRN, Niels Fisker NIELSEN
  • Compositions and Methods for Modulation of ATXN3 Expression
    Publication number: 20150315595
    Abstract: Disclosed are oligonucleotides which target and hybridize to nucleic acid molecules encoding A TXNJ, leading to reduced expression of ATXN3. Reduction in the expression of aberrant ATXN3 is beneficial for the treatment of certain medical disorders, such as spinocerebellar ataxia 3. In particular embodiments, modulating the expression of an aberrant A TXN3 allele or transcript, for example, restores normal function of, for example, Purkinje cells or spinal cord neurons. The oligonucleotides of the present invention and the methods of using such oligonucleotides to modulate the expression of aberrant or expanded A TXN3 provide a means of improving the survival and morbidity associated with, or even curing, expression of an aberrant A TXN3 allele or transcript such as, for example, spinocerebellar ataxia-type 3 (SCA3).
    Type: Application
    Filed: March 12, 2013
    Publication date: November 5, 2015
    Applicant: SANTARIS PHARMA A/S
    Inventors: Nathalie Uzcategui, Maj Hedtjarn, Jens Bo Rode Hansen
  • COMPOSITIONS AND METHODS FOR MODULATION OF FGFR3 EXPRESSION
    Publication number: 20150307886
    Abstract: Disclosed are oligonucleotides which target and hybridize to nucleic acid molecules encoding FGFR3, leading to reduced expression of FGFR3. Reduction in the aberrant expression of FGFR3 is beneficial for the treatment of certain medical disorders, such as achondroplasia.
    Type: Application
    Filed: November 25, 2013
    Publication date: October 29, 2015
    Inventors: Maj Hedtjarn, Soren Ottosen
  • Short oligomer antagonist compounds for the modulation of target mRNA
    Patent number: 8580756
    Abstract: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: November 12, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Henrik Orum, Henrik Frydenlund Hansen, Ellen Marie Straarup, Niels Fisker Nielsen, Maj Hedtjärn
  • RNA antagonist compounds for the modulation of PIK3CA expression
    Patent number: 8450291
    Abstract: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using the oligomers, including methods of treatment.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: May 28, 2013
    Assignee: Santaris Pharma A/S
    Inventor: Maj Hedtjarn
  • RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3
    Publication number: 20120295955
    Abstract: The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
    Type: Application
    Filed: June 22, 2012
    Publication date: November 22, 2012
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.
    Inventor: Maj Hedtjarn
  • RNA antagonist compounds for the modulation of HER3
    Patent number: 8268793
    Abstract: The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: September 18, 2012
    Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.
    Inventor: Maj Hedtjarn
  • RNA ANTAGONISTS TARGETING GLI2
    Publication number: 20110124709
    Abstract: The present invention relates to oligomer compounds (oligomers), which target GLI2 mRNA in a cell, leading to reduced expression of GLI2. Reduction of GLI2 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: July 15, 2009
    Publication date: May 26, 2011
    Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/S
    Inventor: Maj Hedtjarn
  • RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION
    Publication number: 20110077285
    Abstract: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using the oligomers, including methods of treatment.
    Type: Application
    Filed: November 17, 2010
    Publication date: March 31, 2011
    Applicants: ENZON PHARMACEUTICALS, INC., SANTARIS PHARMA A/S
    Inventor: Maj Hedtjarn
  • RNA antagonist compounds for the modulation of PIK3CA expression
    Patent number: 7863437
    Abstract: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: January 4, 2011
    Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S
    Inventor: Maj Hedtjarn
  • SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA
    Publication number: 20100249219
    Abstract: The present invention relates to oligomeric compounds (oligomers) of 12, 13 or 14 nucleotides in length, which target Hif-1alpha mRNA in a cell, leading to reduced expression of Hif-1alpha. Reduction of Hif-1alpha expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: April 2, 2010
    Publication date: September 30, 2010
    Inventors: Maj HEDTJÄRN, Jens Bo Rode Hansen
  • Short RNA Antagonist Compounds for the Modulation of Target mRNA
    Publication number: 20100210712
    Abstract: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.
    Type: Application
    Filed: March 19, 2008
    Publication date: August 19, 2010
    Applicant: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Henrik Frydenlund Hansen, Ellen Marie Straarup, Niels Fisker Nielsen, Maj Hedtjarn
  • RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION
    Publication number: 20090192110
    Abstract: The present invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of PIK3CA using said oligomers, including methods of treatment.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 30, 2009
    Inventor: Maj Hedtjarn
  • RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3
    Publication number: 20080318894
    Abstract: The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
    Type: Application
    Filed: May 9, 2008
    Publication date: December 25, 2008
    Applicant: Santaris Pharma A/S
    Inventor: Maj Hedtjarn